The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Defining the clinical course of multiple sclerosis: The 2013 revisions
Open accessAbstract
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PPMS (10-15% of patients) is characterised by an insidious, slowly progressive increase in neurological disability over time, usually without relapses.2”
From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“At this time it is considered essential that a diagnosis of MS only be made in a patient who has symptoms suggestive of demyelination. 2”
From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [2]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Misdiagnosis of MS remains an issue in clinical practice. 8-11”
From Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (2018) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Self-citationDefining the clinical course of multiple sclerosis
LUBLIN, F. D., & Reingold, S. C. (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,762
Self-citationB-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citationJacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,485
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, Ó., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,042
Self-citationProgressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Natural history of multiple sclerosis: a unifying concept
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awl007 · Cited by 901
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H., Miller, D., Montalbán, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237641.33768.8d · Cited by 677
Self-citationIncidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome
Okuda, D. T., Mowry, E. M., Beheshtian, A., Waubant, E., Baranzini, S. E., Goodin, D. S., Hauser, S. L., & Pelletier, D. (2009) · Neurology · doi:10.1212/01.wnl.0000335764.14513.1a · Cited by 642
Self-citation
Cited by
Sorted by citations
Items 301–400 of 1,007
Peripheral blood biomarkers in multiple sclerosis
D’Ambrosio, A., Pontecorvo, S., Colasanti, T., Zamboni, S., Francia, A., & Margutti, P. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.07.014 · Cited by 70
An emerging potential of metabolomics in multiple sclerosis: a comprehensive overview
Zahoor, I., Rui, B., Khan, J. A., Datta, I., & Giri, S. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03733-2 · Cited by 76
Interventions for preventing falls in people with multiple sclerosis
Hayes, S., Galvin, R., Kennedy, C. M., Finlayson, M. L., McGuigan, C., Walsh, C., & Coote, S. B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012475.pub2 · Cited by 69
The link of inflammation and neurodegeneration in progressive multiple sclerosis
Pérez‐Cerdá, F., Sánchez‐Gómez, M. V., & Matute, C. (2016) · Multiple Sclerosis and Demyelinating Disorders · doi:10.1186/s40893-016-0012-0 · Cited by 68
Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis
Sellebjerg, F. T., Blinkenberg, M., & Sørensen, P. S. (2020) · CNS Drugs · doi:10.1007/s40263-020-00704-w · Cited by 72
Self-citationSamjoo, I. A., Worthington, E., Drudge, C., Zhao, M., Cameron, C. G., Häring, D. A., Stoneman, D., Klotz, L., & Adlard, N. (2020) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0122 · Cited by 68
Bar‐Or, A., Wiendl, H., Montalbán, X., Álvarez, E., Davydovskaya, M. V., Delgado, S. R., Evdoshenko, E., Giedraitienė, N., Gross‐Paju, K., Haldre, S., et al. (2021) · Multiple Sclerosis Journal · doi:10.1177/13524585211044479 · Cited by 69
Validation of Rapid Magnetic Resonance Myelin Imaging in Multiple Sclerosis
Ouellette, R., Mangeat, G., Polyak, I., Warntjes, M. J. B., Forslin, Y., Bergendal, Å., Plattén, M., Uppman, M., Treaba, C. A., Cohen‐Adad, J., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25705 · Cited by 68
Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients
Fitzner, B., Hecker, M., & Zettl, U. K. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.06.001 · Cited by 69
Galea, I., Ward, N., & Heesen, C. (2015) · BMJ · doi:10.1136/bmj.h1765 · Cited by 67
Neuromodulation in multiple sclerosis
Abboud, H., Hill, E., Siddiqui, J., Serra, A., & Walter, B. L. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517736150 · Cited by 69
Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study
Yamout, B., El-Ayoubi, N. K., Nicolas, J., Kouzi, Y. E., Khoury, S. J., & Zeineddine, M. M. (2018) · Journal of Immunology Research · doi:10.1155/2018/9084759 · Cited by 68
Advances in the Treatment of Multiple Sclerosis
Goldschmidt, C. H., & McGinley, M. (2020) · Neurologic Clinics · doi:10.1016/j.ncl.2020.09.002 · Cited by 75
2017 McDonald MS diagnostic criteria: Evidence-based revisions
Carroll, W. M. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458517751861 · Cited by 71
The Transition From First-Line to Second-Line Therapy in Multiple Sclerosis
Dörr, J., & Paul, F. (2015) · Current Treatment Options in Neurology · doi:10.1007/s11940-015-0354-5 · Cited by 66
Kerbrat, A., Gros, C., Badji, A., Bannier, É., Galassi, F., Combès, B., Chouteau, R., Labauge, P. M., Ayrignac, X., Dalliere, C. C., et al. (2020) · Brain · doi:10.1093/brain/awaa162 · Cited by 73
Relationship Between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis
Lie, I. A., Weeda, M. M., Mattiesing, R. M., Mol, M. A. E., Pouwels, P. J. W., Barkhof, F., Torkildsen, Ø., Bø, L., Myhr, K., & Vrenken, H. (2022) · Neurology · doi:10.1212/wnl.0000000000200006 · Cited by 66
Self-citationSwanberg, K. M., Landheer, K., Pitt, D., & Juchem, C. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01173 · Cited by 67
Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis
Prosperini, L., Ruggieri, S., Haggiag, S., Tortorella, C., Pozzilli, C., & Gasperini, C. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001059 · Cited by 65
Self-citationSamjoo, I. A., Drudge, C., Walsh, S., Tiwari, S., Brennan, R., Boer, I., Häring, D. A., Klotz, L., Adlard, N., & Banhazi, J. (2023) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2023-0016 · Cited by 65
Air pollution is associated to the multiple sclerosis inflammatory activity as measured by brain MRI
Bergamaschi, R., Cortese, A., Pichiecchio, A., Berzolari, F. G., Borrelli, P., Mallucci, G., Bollati, V., Romani, A., Nosari, G., Villa, S., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517726866 · Cited by 65
Genovese, A. V., Hagemeier, J., Bergsland, N., Jakimovski, D., Dwyer, M. G., Ramasamy, D. P., Lizarraga, A., Hojnacki, D. W., Kolb, C., Weinstock‐Guttman, B., et al. (2019) · Radiology · doi:10.1148/radiol.2019190306 · Cited by 66
Ginseng polysaccharides: A potential neuroprotective agent
Wang, N., Wang, X., He, M., Zheng, W., Qi, D., Zhang, Y., & Han, C. (2020) · Journal of Ginseng Research · doi:10.1016/j.jgr.2020.09.002 · Cited by 64
Role of environmental factors in multiple sclerosis
Zarghami, A., Li, Y., Claflin, S. B., van der Mei, I. A. F., & Taylor, B. V. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1978843 · Cited by 66
Fingolimod for relapsing-remitting multiple sclerosis
Mantia, L. L., Tramacere, I., Firwana, B., Pacchetti, I., Palumbo, R. A., & Filippini, G. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009371.pub2 · Cited by 67
Illuminating vitamin D effects on B cells – the multiple sclerosis perspective
Rolf, L., Muris, A., Hupperts, R., & Damoiseaux, J. G. M. C. (2015) · Immunology · doi:10.1111/imm.12572 · Cited by 65
Multiple sclerosis: Diagnosis and Differrential Diagnosis
Ömerhoca, S., Akkaş, S. Y., & Icen, N. K. (2018) · Nöro Psikiyatri Arşivi · doi:10.29399/npa.23418 · Cited by 76
Rossor, T. E., Benetou, C., Wright, S. K., Duignan, S. M., Lascelles, K., Robinson, R. A., Das, K., Ciccarelli, O., Wassmer, E., Hemingway, C. A., et al. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458518823486 · Cited by 64
Multiple Sclerosis Performance Test: Technical Development and Usability
Rhodes, J., Schindler, D., Rao, S. M., Venegas, F., Bruzik, E. T., Gabel, W., Williams, J. R., Phillips, G. A., Mullen, C. C., Freiburger, J. L., et al. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00958-x · Cited by 64
Self-citationRetinal and brain microglia in multiple sclerosis and neurodegeneration
Choi, S., Guo, L., & Cordeiro, M. F. (2021) · Cells · doi:10.3390/cells10061507 · Cited by 63
Multiple sclerosis is linked to MAPKERK overactivity in microglia
ten Bosch, G. J. A., Bolk, J., Hart, B. A. ‘., & Laman, J. D. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02080-4 · Cited by 63
NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study
Uphaus, T., Steffen, F., Muthuraman, M., Ripfel, N., Fleischer, V., Groppa, S., Ruck, T., Meuth, S. G., Pul, R., Kleinschnitz, C., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103590 · Cited by 63
Therapeutic Yoga: Symptom Management for Multiple Sclerosis
Rogers, K. A., & MacDonald, M. (2015) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2015.0015 · Cited by 63
Sellebjerg, F. T., Royen, L., Sørensen, P. S., Oturai, A. B., & Jensen, P. E. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518794308 · Cited by 63
Self-citationMarques, V. D., dos Passos, G. R., Mendes, M. F., Callegaro, D., Lana–Peixoto, M. A., Comini-Frota, E. R., Vasconcelos, C. C. F., Sato, D. K., Ferreira, M. L. B., Parolin, M. K. F., et al. (2018) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20180078 · Cited by 66
Natural killer cells in multiple sclerosis: A review
Mimpen, M., Smolders, J., Hupperts, R., & Damoiseaux, J. G. M. C. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.02.012 · Cited by 62
Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy
Mansilla, M. J., Presas‐Rodríguez, S., Teniente‐Serra, A., González-Larreategui, Í., Quirant‐Sánchez, B., Fondelli, F., Djedović, N., Iwaszkiewicz‐Grześ, D., Chwojnicki, K., Miljković, D. M., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00618-z · Cited by 64
Bravo-Miana, R. D. C., Arizaga-Echebarria, J. K., & Otaegui, D. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00418-9 · Cited by 63
Brain Plasticity Effects of Neuromodulation Against Multiple Sclerosis Fatigue
Tecchio, F., Cancelli, A., Cottone, C., Ferrucci, R., Vergari, M., Zito, G., Pasqualetti, P., Filippi, M. M., Ghazaryan, A., Lupoi, D., et al. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00141 · Cited by 62
Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 – continuity and change
Hartung, H., Graf, J., Aktaş, O., Mareš, J., & Barnett, M. H. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000699 · Cited by 64
Rammohan, K. W., Coyle, P. K., Sylvester, E., Galazka, A. R., Dangond, F., Grosso, M., & Leist, T. P. (2020) · Drugs · doi:10.1007/s40265-020-01422-9 · Cited by 64
Mousavi-Shirazi-Fard, Z., Mazloom, Z., Izadi, S., & Fararouei, M. (2020) · International Journal of Neuroscience · doi:10.1080/00207454.2020.1750398 · Cited by 63
Reproductive history and progressive multiple sclerosis risk in women
Zeydan, B., Atkinson, E. J., Weis, D., Smith, C. Y., Rocca, L. G., Rocca, W. A., Keegan, B. M., Weinshenker, B. G., Kantarci, K., & Kantarci, O. H. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa185 · Cited by 61
Saposnik, G., Sempere, Á. P., Prefasi, D., Selchen, D. H., Ruff, C. C., Mauriño, J., & Tobler, P. N. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00065 · Cited by 61
Cerebellar lobule atrophy and disability in progressive MS
Cocozza, S., Petracca, M., Mormina, E., Buyukturkoglu, K., Podranski, K., Heinig, M. M., Pontillo, G., Russo, C., Tedeschi, E., Russo, C. V., et al. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316448 · Cited by 61
Self-citationMetformin as a Potential Agent in the Treatment of Multiple Sclerosis
Dziedzic, A., Saluk, J., Miller, E. D., & Bijak, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21175957 · Cited by 62
Burt, R. K., Han, X., Quigley, K., Helenowski, I., & Balabanov, R. D. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10820-2 · Cited by 60
Altered substrate metabolism in neurodegenerative disease: new insights from metabolic imaging
Cleland, N. R. W., Al‐Juboori, S. I., Dobrinskikh, E., & Bruce, K. D. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02305-w · Cited by 62
For the Golden Study Group, Comı, G., Patti, F., Rocca, M. A., Mattioli, F., Amato, M. P., Gallo, P., Centonze, D., Pozzilli, C., Saccà, F., et al. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8642-5 · Cited by 60
Self-citationDisease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: A Network Meta-Analysis
Lucchetta, R. C., Tonin, F. S., Borba, H. H. L., Leonart, L. P., Ferreira, V. L., Bonetti, A. D. F., Riveros, B. S., Becker, J., Pontarolo, R., Fernández-Llimós, F., et al. (2018) · CNS Drugs · doi:10.1007/s40263-018-0541-5 · Cited by 62
Milo, R., Korczyn, A. D., Manouchehri, N., & Stüve, O. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519886943 · Cited by 61
Self-citationTaylor, E. C., & Taylor‐Piliae, R. E. (2017) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2017.03.001 · Cited by 59
Targeting B Cells to Modify MS, NMOSD, and MOGAD
Graf, J., Mareš, J., Barnett, M. H., Aktaş, O., Albrecht, P., Zamvil, S. S., & Hartung, H. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000918 · Cited by 59
Dumitrescu, L., Papathanasiou, A. I., Coclitu, C., Garjani, A., Evangelou, N., Constantinescu, C. S., Popescu, B. O., & Tănăsescu, R. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2178898 · Cited by 60
Morel, A., Rywaniak, J., Bijak, M., Miller, E. D., Niwald, M., & Saluk, J. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-2955-7 · Cited by 59
Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study
Pontillo, G., Cocozza, S., Lanzillo, R., Russo, C., Stasi, M. D., Paolella, C., Vola, E. A., Criscuolo, C., Borrelli, P., Palma, G., et al. (2018) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5915 · Cited by 59
The emerging role of neutrophils in neurodegeneration
Rossi, B., Constantin, G., & Zenaro, E. (2019) · Immunobiology · doi:10.1016/j.imbio.2019.10.014 · Cited by 60
Dickerson, E. C., Davenport, M. S., Syed, F., Stüve, O., Cohen, J. A., Rinker, J. R., Goldman, M. D., Segal, B. M., & Foerster, B. R. (2016) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2016.09.037 · Cited by 58
Self-citationCross-cultural Adaptation, Reliability, and Validity of the BICAMS in Brazil
Spedo, C. T., Frndak, S., Marques, V. D., Foss, M. P., Pereira, D. A., Carvalho, L. D. F., Guerreiro, C. T., Conde, R. M., Fusco, T., Pereira, A. J. G., et al. (2015) · The Clinical Neuropsychologist · doi:10.1080/13854046.2015.1093173 · Cited by 58
Multiple sclerosis and sexual dysfunction: A need for further education and interdisciplinary care
Delaney, K. E., & Donovan, J. M. (2017) · Neurorehabilitation · doi:10.3233/nre-172200 · Cited by 58
Haschka, D., Tymoszuk, P., Bsteh, G., Petzer, V., Berek, K., Theurl, I., Berger, T., & Weiß, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00594 · Cited by 59
Medical Digital Twin: A Review on Technical Principles and Clinical Applications
Tortora, M., Pacchiano, F., Ferraciolli, S. F., Criscuolo, S., Gagliardo, C., Jaber, K., Angelicchio, M., Briganti, F., Caranci, F., Tortora, F., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020324 · Cited by 58
Defining active progressive multiple sclerosis
Sellebjerg, F. T., Börnsen, L. S., Ammitzbøll, C., Nielsen, J. E., Vinther‐Jensen, T., Hjermind, L. E., von Essen, M. R., Ratzer, R. L., Sørensen, P. S., & Christensen, J. R. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517726592 · Cited by 57
Self-citationKotelnikova, E. A., Kiani, N. A., Messinis, D. E., Pertsovskaya, I., Pliaka, V., Bernardo-Faura, M., Rinas, M., Vila, G., Zubizarreta, I., Pulido-Valdeolivas, I., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818347116 · Cited by 58
Phases and Phenotypes of Multiple Sclerosis
Kantarci, O. H. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000737 · Cited by 62
Crescentini, C., Matiz, A., Cimenti, M., Pascoli, E., Eleopra, R., & Fabbro, F. (2018) · International Journal of MS Care · doi:10.7224/1537-2073.2016-093 · Cited by 56
Microglia as therapeutic target in central nervous system disorders
Fatoba, O., Itokazu, T., & Yamashita, T. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.07.004 · Cited by 57
Real‐world evaluation of ocrelizumab in multiple sclerosis: A systematic review
Montalbán, X., Matthews, P. M., Simpson, A., Petrie, J. L., Sammon, C., Ramagopalan, S. V., Disanto, G., & Kühle, J. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51732 · Cited by 56
Ransohoff, R. M. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.02.002 · Cited by 57
Gómez-Melero, S., Caballero‐Villarraso, J., Escribano, B. M., Galvao-Carmona, A., Túnez, I., & Agüera, E. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113321 · Cited by 63
Broersma, F., Oeseburg, B., Dijkstra, J. W. E., & Wynia, K. (2017) · Clinical Rehabilitation · doi:10.1177/0269215517730670 · Cited by 60
Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis
Jia, X., Madireddy, L., Caillier, S. J., Santaniello, A., Esposito, F., Comı, G., Stüve, O., Zhou, Y., Taylor, B. V., Kilpatrick, T. J., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25263 · Cited by 56
Self-citationDiffusion tensor imaging and disability progression in multiple sclerosis: A 4‐year follow‐up study
Kolasa, M., Hakulinen, U., Brander, A., Hagman, S., Dastidar, P., Elovaara, I., & Sumelahti, M. (2018) · Brain and Behavior · doi:10.1002/brb3.1194 · Cited by 56
Amato, M. P., Prestipino, E., Bellinvia, A., Niccolai, C., Razzolini, L., Pastò, L., Fratangelo, R., Tudisco, L., Fonderico, M., Mattiolo, P. L., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222929 · Cited by 58
Multiple Sclerosis Performance Test: validation of self‐administered neuroperformance modules
Rao, S. M., Galioto, R., Sokolowski, M. J., McGinley, M., Freiburger, J. L., Weber, M. E., Dey, T., Mourany, L., Schindler, D., Reece, C., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14162 · Cited by 56
Self-citationIntrathecally produced CXCL13: A predictive biomarker in multiple sclerosis
DiSano, K. D., Gilli, F., & Pachner, A. R. (2020) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217320981396 · Cited by 58
Blood Neurofilament Light in Progressive Multiple Sclerosis
Leppert, D., Kropshofer, H., Häring, D. A., Dahlke, F., Patil, A., Meinert, R., Tomic, D., Kappos, L., & Kühle, J. (2022) · Neurology · doi:10.1212/wnl.0000000000200258 · Cited by 55
Self-citationFatigue and Fatigability in Persons With Multiple Sclerosis
Zijdewind, I., Prak, R. F., & Wolkorte, R. (2016) · Exercise and Sport Sciences Reviews · doi:10.1249/jes.0000000000000088 · Cited by 58
The therapeutic use of non-invasive brain stimulation in multiple sclerosis – a review
Iodice, R., Manganelli, F., & Dubbioso, R. (2017) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-170735 · Cited by 55
Adamec, I., Crnošija, L., Junaković, A., Skorić, M. K., & Habek, M. (2018) · Clinical Neurophysiology · doi:10.1016/j.clinph.2018.05.009 · Cited by 55
Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis
Baldassari, L. E., & Fox, R. J. (2018) · Drugs · doi:10.1007/s40265-018-0984-5 · Cited by 58
Self-citationDiagnosis, Differential Diagnosis, and Misdiagnosis of Multiple Sclerosis
Solomon, A. J. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000728 · Cited by 57
Murali, N., Browne, R. W., Maxwell, K. F., Bodziak, M. L., Jakimovski, D., Hagemeier, J., Bergsland, N., Weinstock‐Guttman, B., Zivadinov, R., & Ramanathan, M. K. (2019) · European Journal of Neurology · doi:10.1111/ene.14055 · Cited by 55
Ormstad, H., Simonsen, C. S., Broch, L., Maes, M. H. J., Anderson, G., & Celius, E. G. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102533 · Cited by 56
Podbielska, M., O’Keeffe, J., & Pokryszko‐Dragan, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147319 · Cited by 55
Schreiber, K. I., Magyari, M., Sellebjerg, F. T., Iversen, P., Garde, E., Madsen, C. G., Börnsen, L. S., Christensen, J. R., Ratzer, R. L., Siebner, H. R., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516661048 · Cited by 54
Self-citationHigh dose biotin as treatment for progressive multiple sclerosis
Birnbaum, G., & Stulc, J. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.09.030 · Cited by 54
Wolinsky, J. S., Montalbán, X., Hauser, S. L., Giovannoni, G., Vermersch, P., Bernasconi, C., Deol‐Bhullar, G., Garren, H., Chin, P., Belachew, S. M., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25313 · Cited by 54
Self-citationLearning from other autoimmunities to understand targeting of B cells to control multiple sclerosis
Baker, D., Pryce, G., Amor, S., Giovannoni, G., & Schmierer, K. (2018) · Brain · doi:10.1093/brain/awy239 · Cited by 54
Gray matter microglial activation in relapsing vs progressive MS
Singhal, T., O’Connor, K., Dubey, S., Pan, H., Chu, R., Hurwitz, S., Cicero, S., Tauhid, S., Silbersweig, D., Stern, E. R., et al. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000587 · Cited by 54
Bruschi, N., Boffa, G., & Inglese, M. (2020) · European Radiology Experimental · doi:10.1186/s41747-020-00186-x · Cited by 58
Self-citationHealth-related quality of life of multiple sclerosis patients: a European multi-country study
Visser, L. A., Louapre, C., Groot, C. A. U., & Redekop, K. (2021) · Archives of Public Health · doi:10.1186/s13690-021-00561-z · Cited by 54
Diagnosis and treatment of progressive multiple sclerosis: A position paper
Pozzilli, C., Pugliatti, M., Vermersch, P., Grigoriadis, N., Alkhawajah, M. M., Airas, L. M., & Oreja‐Guevara, C. (2022) · European Journal of Neurology · doi:10.1111/ene.15593 · Cited by 61
Self-citationSmoking and worsening disability in multiple sclerosis: A meta-analysis
Heydarpour, P., Manouchehrinia, A., Beiki, O., Mousavi, S. E., Abdolalizadeh, A., Moradi‐Lakeh, M., & Sahraian, M. A. (2018) · Acta Neurologica Scandinavica · doi:10.1111/ane.12916 · Cited by 53
Early predictors of conversion to secondary progressive multiple sclerosis
Barzegar, M., Najdaghi, S., Afshari-Safavi, A., Nehzat, N., Mirmosayyeb, O., & Shaygannejad, V. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103115 · Cited by 52
Bridel, C., Leurs, C. E., van Lierop, Z. Y. G. J., van Kempen, Z. L. E., Dekker, I., Twaalfhoven, H. A. M., Moraal, B., Barkhof, F., Uitdehaag, B. M. J., Killestein, J., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012752 · Cited by 52
Self-citationLeone, M. A., Gelati, M., Profico, D. C., Gobbi, C., Pravatà, E., Copetti, M., Conti, C. A., Abate, L., Amoruso, L., Apollo, F., et al. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.11.001 · Cited by 53
Distinguishing Susac’s syndrome from multiple sclerosis
Buzzard, K. A., Reddel, S., Yiannikas, C., Riminton, S., Barnett, M. H., & Hardy, T. A. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7628-9 · Cited by 52
Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?
Gupta, S., Zivadinov, R., Ramanathan, M. K., & Weinstock‐Guttman, B. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1180978 · Cited by 52
Environmental control of autoimmune inflammation in the central nervous system
Rothhammer, V., & Quintana, F. J. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.09.002 · Cited by 52
Metadata
- Authors
- Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., Bebo, B., Calabresi, P. A., Clanet, M., Comi, G., Fox, R. J., Freedman, M. S., Goodman, A. D., Inglese, M., Kappos, L., Kieseier, B. C., Lincoln, J. A., Lubetzki, C., Miller, A. E., Montalban, X., O'Connor, P. W., Petkau, J., Pozzilli, C., Rudick, R. A., Sormani, M. P., Stüve, O., Waubant, E., & Polman, C. H.
- Affiliations
- Cleveland Clinic (US)
- From the Corinne Goldsmith Dickenson Center for Multiple Sclerosis (F.D.L., A.E.M.), Icahn School of Medicine at Mount Sinai, New York, NY; Scientific and Clinical Review Associates, LLC (S.C.R.), Salisbury, CT; The Mellen Center for MS Treatment and Research (J.A.C., R.J.F., R.A.R.), Cleveland Clinic, OH; the Department of Biostatistics (G.R.C.), University of Alabama at Birmingham; the Danish Multiple Sclerosis Center (P.S.S.), Department of Neurology, Copenhagen University Hospital Rigshospitalet...
- Corresponding author
- Lublin, Fred D.
- ORCID
- Lublin, Fred D.
- Reingold, Stephen C.
- Cohen, Jeffrey A.
- Cutter, Gary R.
- Sørensen, Per Soelberg
- Thompson, Alan J.
- Wolinsky, Jerry S.
- Balcer, Laura J.
- Banwell, Brenda
- Barkhof, Frederik
- Bebo, Bruce
- Calabresi, Peter A.
- Comi, Giancarlo
- Fox, Robert J.
- Goodman, Andrew D.
- Inglese, Matilde
- Kappos, Ludwig
- Lincoln, John A.
- Lubetzki, Catherine
- Miller, Aaron E.
- O'Connor, Paul W.
- Pozzilli, Carlo
- Rudick, Richard A.
- Sormani, Maria Pia
- Stüve, Olaf
- Waubant, Emmanuelle
- Polman, Chris H.
- Venue
- Neurology
- Published
- 2014-07-15
- Volume
- 83
- Issue
- 3
- Pages
- 278-286
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC4117366
- OpenAlex
- W2105206040
- Cited by
- 3,177
- References
- 32
- Citations by year
- 2026: 229 · 2025: 266 · 2024: 335 · 2023: 308 · 2022: 333 · 2021: 333 · 2020: 298 · 2019: 274 · 2018: 232 · 2017: 236 · 2016: 193 · 2015: 105 · 2014: 27
- FWCI
- 139.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Neurology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Multiple Sclerosis Society
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Celgene
- F. Hoffmann-La Roche
- Cleveland Clinic
- Novartis Pharmaceuticals Corporation
- University of Alabama at Birmingham
- European Committee for Treatment and Research in Multiple Sclerosis
- Wellcome Trust
- Ironwood Pharmaceuticals, Incorporated
- University of Alabama
- Myelin Repair Foundation
- University of Texas Health Science Center at Houston
- GW Pharmaceuticals
- Acorda Therapeutics
- Prothena
- Glenmark Pharmaceuticals
- National Institute for Health and Care Research
- Multiple Sclerosis Society
- University of Cambridge
- European Commission
- Bayer HealthCare
- Wolfson Foundation
- National Research Foundation
- Eisai
- Multiple Sclerosis International Federation
- Schweizerische Multiple Sklerose Gesellschaft
- Sun Pharma
- Serono Symposia International Foundation
- Grifols
- National Institutes of Health
- Genentech
- EMD Serono
- Bayer Canada
- Sanofi Genzyme
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada
- Medical Research Council
- National Heart, Lung, and Blood Institute
- National Institute of Neurological Disorders and Stroke
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- multiple sclerosis, clinical course, disease phenotypes, clinical trial design, relapse rate, disease activity, disease progression, MRI findings, biomarkers
- MeSH terms
- Clinical Trials as Topic, Humans, Multiple Sclerosis, Societies, Medical, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
